EQRx chairman Alexis Borisy (L) and CEO Melanie Nallichieri

EQRx adds ar­mor to its dis­count check­point in­hibitor sub­mis­sion, nail­ing sur­vival mark in key study

The rules say you can’t dis­rupt any mar­ket un­less you are, in fact, a part of that mar­ket — and self-styled drug pric­ing dis­rup­tor EQRx is one step clos­er to do­ing just that.

A com­bi­na­tion of EQRx and CStone’s PD-(L)1 drug sug­e­mal­imab and chemother­a­py sig­nif­i­cant­ly pro­longed pa­tients’ lives over place­bo in pa­tients with new­ly di­ag­nosed stage IV non-small cell lung can­cer, ac­cord­ing to up­dat­ed da­ta from the Phase III GEM­STONE-302 study un­veiled Tues­day evening.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.